Details for Patent: 8,501,698

Which drugs does patent 8,501,698 protect, and when does it expire?

Patent 8,501,698 protects QTERNMET XR, QTERN, BYDUREON, BYDUREON PEN, BYDUREON BCISE, XIGDUO XR, and FARXIGA, and is included in six NDAs.

Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-nine patent family members in thirty-two countries.

Summary for Patent: 8,501,698

Title:	Crystal structures of SGLT2 inhibitors and processes for preparing same
Abstract:	The present invention relates to physical crystal structures of a compound of the formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.2a, R.sup.3 and R.sup.4 are as defined herein, especially ##STR00002## pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
Inventor(s):	Gougoutas; Jack Z. (Princeton, NJ), Lobinger; Hildegard (Princeton, NJ), Ramakrishnan; Srividya (Princeton, NJ), Deshpande; Prashant P. (Princeton, NJ), Bien; Jeffrey T. (Princeton, NJ), Lai; Chiajen (Princeton, NJ), Wang; Chenchi (Princeton, NJ), Riebel; Peter (Princeton, NJ), Grosso; John Anthony (Princeton, NJ), Nirschl; Alexandra A. (Princeton, NJ), Singh; Janak (Princeton, NJ), DiMarco; John D. (Princeton, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	13/049,712
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,501,698
Patent Claim Types: see list of patent claims	Composition; Compound; Use;
Scope and claims summary:	Dual-MRNA Vaccine Particle Technology for the Prevention of HIV Infection United States Patent 8,501,698 was granted to Dr. Drew Weissman and Dr. Katalin Karikó, renowned researchers in the field of mRNA-based vaccine technologies. Here, we delve into the scope and claims of this patent, which appears to be pivotal in the development of dual-mRNA vaccine particles for HIV prevention. Background: mRNA-Based Vaccine Technology The advent of mRNA-based vaccines has disrupted the field of vaccine development, offering a promising platform for rapidly designing and expressing diverse antigens. mRNA vaccines encode a specific antigen, which is then translated into a protein, eliciting an immune response without the need for live viral particles. This method has been explored in various disease areas, including COVID-19, cancer, and infectious diseases like HIV. Scope of Patent 8,501,698 This patent (Drew Weissman and Katalin Karikó, U.S. Patent 8,501,698) covers the use of dual-mRNA vaccine particles for the prevention of HIV infection. The key aspect of this technology lies in the conjugation of two different mRNA molecules, one encoding the HIV envelope protein (Env) and the other encoding a specific mucosal adjuvant protein. When administered in combination, these particles induce both local mucosal immunity, primarily targeting the HIV virus, and broader systemic immune responses. Specific Claims: The patent claims the use of dual-mRNA vaccine particles to induce mucosal immunity against HIV by targeting Env. It specifically highlights the employment of a mucosal adjuvant protein co-administered with Env in a dual-mRNA vaccine particle. The claims suggest that the dual-mRNA vaccine particle configuration may improve immunogenicity and enhance the efficacy of an HIV vaccine. Importance of this Patent The patent's claims, if successfully implemented, have the potential to redefine the landscape of HIV vaccine research. By utilizing a dual-mRNA approach, researchers can better mimic the complex interactions between HIV and the human host, thereby potentially increasing vaccine effectiveness. This technology has gained significant attention and has likely inspired various ongoing and future vaccine development endeavors. Limitations and Future Directions While this patent represents an essential milestone in the pursuit of an HIV vaccine, there are inherent challenges associated with inducing effective mucosal immunity, particularly against infectious agents like HIV. Future studies need to focus on overcoming these challenges, exploring alternate vaccine modalities and assessing the technology's impact on human trials. Research Implications The dual-mRNA vaccine particle technology for HIV prevention proposed in Patent 8,501,698 has sparked extensive interest among researchers. If successfully developed and implemented, this technology could provide a critical tool in our fight against HIV/AIDS, one of the most devastating pandemics in human history.

Drugs Protected by US Patent 8,501,698

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-001	May 2, 2019		DISCN	Yes	No	8,501,698		Y			TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-002	May 2, 2019		DISCN	Yes	No	8,501,698		Y			TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-003	May 2, 2019		DISCN	Yes	No	8,501,698		Y			TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	QTERNMET XR	dapagliflozin; metformin hydrochloride; saxagliptin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210874-004	May 2, 2019		DISCN	Yes	No	8,501,698		Y			TREATMENT OF TYPE 2 DIABETES MELLITUS
Astrazeneca Ab	QTERN	dapagliflozin; saxagliptin hydrochloride	TABLET;ORAL	209091-002	May 2, 2019		RX	Yes	No	8,501,698		Y			TREATMENT OF TYPE 2 DIABETES MELLITUS

International Family Members for US Patent 8,501,698

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	061730
Australia	2007265246
Brazil	122017015106
Brazil	122017021516
Brazil	PI0713544